Searchable abstracts of presentations at key conferences in endocrinology

ea0032p225 | Clinical case reports – Pituitary/Adrenal | ECE2013

Delivery of health child in acromegaly patient with McCune–Albright syndrome treated with lanreotide and pegvisomant during pregnancy

Weiss Vladimir , Hana Vaclav , Marek Josef

Introduction: Acromegaly with GH excess affects up to 20% of the patients with McCune–Albright syndrome (MAS). Surgical treatment for acromegaly in MAS is often difficult because of skull-base dysplasia. Somatostatin analogs are frequently only partially effective and GH receptor antagonist – pegvisomant is more potent in normalizing IGFI levels. Radiotherapy is controversial. Pregnancy in MAS patients is described in literature but no case of successful delivery in ...

ea0037ep751 | Pituitary: clinical | ECE2015

Endonasal endoscopic pituitary adenoma resection

Masopust Vaclav , Netuka David , Benes Vladimir , Bradac Ondrej , Marek Josef , Hana Vaclav , Krsek Michal

Introduction: In the past 10 years, endoscopic resection of pituitary adenomas has become an alternative to microsurgical resection with the additional advantage of increasing the patient’s postoperative comfort. This analysis explored whether endoscopic resection can reduce the risk of postoperative neurohypophyseal dysfunction.Material and methods: We rated and compared the need to administer desmopressin during the first four postoperative days a...

ea0032p31 | Adrenal cortex | ECE2013

Reliability of serum versus salivary cortisol in ACTH test

Kosak Mikulas , Hana Vaclav , Hill Martin , Simunkova Katerina , Lacinova Zdena , Krsek Michal , Marek Josef

Introduction: Salivary cortisol measurement, representing free cortisol, seems to be a promissing alternative method to serum cortisol. Besides its use in the diagnostics of hypercortisolism, it could be of help in evaluation of adrenocortical reserve. It might be useful especially in patients on estrogen replacement, which modulates transcortin and hence total cortisol levels.Aims: Compare the reliability of salivary vs. serum cortisol assessment during...

ea0022p595 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Pituitary functions in patients with chronic subdural hematoma

Kosak Mikulas , Masopust Vaclav , Netuka David , Lacinova Zdenka , Krsek Michal , Marek Josef , Hana Vaclav

Certain degree of hypopituitarism has been revealed in a significant number of patients who suffered traumatic brain injuries or subarachnoid hemorrhage. Microhemorrhages, necrosis, tissue infarcts and vasoconstriction are reported as mechanism of hypothalamo-pituitary dysfunction. Assessment of hypothalamo-pituitary endocrine functions in patients with chronic subdural hematomas has not been published yet, although dysfunction of hypothalamo-pituitary unit can be expected (he...

ea0020p491 | Obesity and Metabolism | ECE2009

Regulation of novel metabolic regulator fibroblast growth factor-21 by body adiposity and hypercortisolemia: studies in patients with obesity and Cushing’s syndrome

Durovcova Viktoria , Krsek Michal , Hana Vaclav , Marek Josef , Bartlova Marketa , Kavalkova Petra , Haluzik Martin

Fibroblast growth factor-21 (FGF-21) is a novel regulator of metabolic homeostasis that improved diabetes compensation and dyslipidemia in diabetic mice and monkeys. However, little is known about its regulation in humans. Cushing’s syndrome (CS) is characterized by endogenous hypercortisolism and is often associated with numerous metabolic abnormalities. The objective of this study was to test the hypothesis that CS is associated with altered levels of FGF 21 that may in...

ea0020p574 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Is it possible to avoid hypopituitarism after the irradiation of pituitary adenomas by the Leksell gamma-knife?

Marek Josef , Jezkova Jana , Hana Vaclav , Krsek Michal , Liscak Roman , Vladyka Vilibald

Radiation therapy is used in the treatment of pituitary adenomas, especially in failures of neurosurgery and pharmacotherapy to reduce the size of adenomas and normalize their hypersecretion. Conventional fractionated radiotherapy has achieved good results, but only after a long latency, with considerable postradiation morbidity and with very frequent appearance of hypopituitarism. The focal stereotactic targeting allowed by Leksell gamma-knife (LGK) was supposed to decrease t...

ea0016p400 | Neuroendocrinology | ECE2008

Impaired microvascular reactivity and endothelial function in patients with Cushing's syndrome

Durovcova Viktoria , Prazny Martin , Jezkova Jana , Horova Eva , Hana Vaclav , Kvasnicka Jan , Pecen Ladislav , Marek Josef , Skrha Jan , Krsek Michal

It is well known that hypercortisolism is associated with increased morbidity and mortality caused predominantly by vascular and atherosclerotic complications. The effect of hypercortisolism on microvasculature is less known. The aim of this study was to evaluate skin microvascular reactivity (MVR) in relation to arterial hypertension, diabetes mellitus and other possible influencing factors (fibrinolysis, oxidative stress and endothelial function) in patients with Cushing&#14...

ea0022p625 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Efficacy and safety of co-administration of lanreotide Autogel 120 mg monthly with pegvisomant weekly in patients with acromegaly partially controlled by somatostatin analogues

van der Lely Aart-Jan , Bernabeu Ignacio , Cap Jan , Caron Philippe , Colao Annamaria , Lesage Catherine , Marek Josef , Neggers Sebastian , Birman Pascal

Recent studies have shown that the co-administration of lanreotide (lan) with pegvisomant (peg) was able to normalise IGF1 secretion in patients with acromegaly who were partial responders to somatostatin analogues (SSAs).Fifty seven subjects with acromegaly (mean age 51.6±12.7 years) not previously controlled by SSAs (either treated by SSAs for at least 6 months with IGF1 > ULN, or on peg for at least 3 months) with IGF1 > 1.2 ULN (n...

ea0035p884 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Register of sellar tumors: RESET: diagnostics and therapy of acromegaly in Czech and Slovak Republics

Hana Vaclav , Svancara Jan , Bandurova Lubomira , Brabec Petr , Cap Jan , Durovcova Viktoria , Dvorakova Eva , Hana Vaclav , Jarkovska Zuzana , Kentos Peter , Klimes Daniel , Krcma Michal , Krsek Michal , Lazurova Ivica , Olsovska Vera , Podoba Jan , Pura Mikulas , Sasikova Michaela , Stary Karel , Strenkova Jana , Siprova Helena , Steno Juraj , Trejbalova Ludmila , Vanuga Peter , Wagnerova Hedviga , Weiss Vladimir , Zeman Dalibor , Dusek Ladislav , Marek Josef

Acromegaly is usually diagnosed after several years of duration. The multimodal therapy – surgery, radiotherpy, pharmacotherapy – is necessary in the majority of patients. Register of sellar tumors (RESET) collecting data of patients from eight tertiary centers in the Czech and Slovak Republics since the year 2000 was established in 2008.Aim of analysis: Evaluation of diagnostics of acromegaly and effectiveness of its treatment in a daily pract...